An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
- Breast Cancer
- Advanced Solid Tumor
At a glance
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- BeOne Medicines
- Enrolment target
- 86
- Started
- 11 December 2025
- Main results due
- 30 September 2029
- Study sites
- 32
- Registry updated
- 28 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Part 1A: Participants with histologically or cytologically confirmed advanced, metastatic breast cancer and other solid tumors who have exhausted, are intolerant of all available standard of care therapies, and/or without available standard of care therapies. * Part 1B and Part 2A: Participants with advanced breast cancer with 1 to 3 prior lines of systemic therapy in the metastatic setting. Prior lines in the advanced/ metastatic setting may not exceed 2 lines of chemotherapy (inclusive of antibody-drug conjugate with cytotoxic payload). * Parts 2B and 2C: Participants with advanced breast cancer enrolled in regions where cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are not approved and/or not available as the first-line treatment and who are CDK4/6 inhibitor treatment naïve and did not receive any previous systemic treatment for advanced disease. * Participants with breast cancer must have histologically or cytologically confirmed advanced breast cancer at the time of most recent testing, based on American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. * Female participants with metastatic breast cancer must be postmenopausal or receiving ovarian function suppression treatment. * Measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Adequate organ function. Exclusion Criteria: * Prior exposure to KAT6A/B or KAT7 inhibitors/degraders. * Patients with active leptomeningeal disease or uncontrolled, untreated brain metastasis. * Participants with any malignancy ≤ 3 years before screening for the study except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively which in the opinion of the investigator is unlikely to require intervention during the study. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
Study sites(32)
University of Alabama At Birmingham Hospital
Birmingham, Alabama, United States
Recruiting
Yale Cancer Center
New Haven, Connecticut, United States
Recruiting
Washington University in St Louis
St Louis, Missouri, United States
Recruiting
Next Oncology Austin
Austin, Texas, United States
Recruiting
The University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Recruiting
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia
Recruiting
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia
Recruiting
Cancer Research South Australia
Adelaide, South Australia, Australia
Recruiting
Austin Health
Heidelberg, Victoria, Australia
Recruiting
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Recruiting
Sun Yat Sen University Cancer Center Huangpu Branch
Guangzhou, Guangdong, China
Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China
Recruiting
Jiangsu Province Hospital Longjiang Branch
Nanjing, Jiangsu, China
Recruiting
Fudan University Shanghai Cancer Centerpudong
Shanghai, Shanghai Municipality, China
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Recruiting
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Recruiting
Istituto Europeo Di Oncologia
Milan, Italy
Recruiting
Istituto Nazionale Tumori Fondazione G Pascale
Naples, Italy
Recruiting
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Recruiting
Istituto Clinico Humanitas
Rozzano, Italy
Recruiting
Auckland City Hospital
Auckland, New Zealand
Recruiting
Hospital Universitario Vall Dhebron
Barcelona, Spain
Recruiting
Next Oncology Barcelona
Barcelona, Spain
Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain
Recruiting
Hospital Clinico San Carlos
Madrid, Spain
Recruiting
Hospital Universitario Virgen de La Victoria
Málaga, Spain
Recruiting
Showing 32 of 32 sites. 32 of the 32 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07222267. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me